Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Purpose
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used in MCL, the current standard of care is to continue administering the drug indefinitely until disease progression. This continuous treatment comes with clinical as well as financial toxicity, which could be especially detrimental in older patients. For patients who achieve a CR after initial zanubrutinib plus rituximab therapy, it may be safe and equally effective to stop treatment and restart zanubrutinib upon disease progression rather than continuing indefinitely in previously untreated older adult patients with MCL.
Condition
- Mantle Cell Lymphoma
Eligibility
- Eligible Ages
- Over 60 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- • Histologically confirmed mantle cell lymphoma with cyclin D1 (BCL1) expression by
immunohistochemical stains and/or t(11;14) by cytogenetics or fluorescence in situ
hybridization (FISH) as confirmed by the enrolling center
- Any stage allowed (stage I-IV)
- Presence of measurable disease, defined as >= 1 nodal lesion that is > 1.5
cm in longest diameter or >= 1 extranodal lesion that is > 1 cm in longest
diameter
- Steroids for management of mantle cell lymphoma are allowed up to a dose
of prednisone 100mg/day (or equivalent) for up to 7 days
- No prior systemic treatment for mantle cell lymphoma
- No prior radiation treatment for stage I MCL
- No prior exposure to a BTK inhibitor or anti-CD20 monoclonal antibody
- No prior stem cell transplant
- Age >= 70 years OR age >= 60 to < 70 years with comorbidities precluding
autologous stem cell transplantation (autoSCT) including at least one of
the following: a) cardiac ejection fraction (EF) < 45%, b) diffusing
capacity for carbon monoxide < 60% predicted; c) creatinine clearance < 70
but > 30ml/minute (min); d) Eastern Cooperative Oncology Group (ECOG)
performance status of 2, which poses an unacceptable risk of toxicity for
high-dose therapy and stem cell transplantation; or e) Cumulative Illness
Rating Scales (CIRS) total score > 6
- ECOG Performance Status 0-2
- Absolute neutrophil count (ANC) >= 750/mm^3 (without growth factor support
within 7 days)
- Platelet count >= 75,000/mm^3 (or >= 50,000/mm^3 for patients with bone
marrow involvement of lymphoma) without growth factor support or
transfusion within 7 days
- Creatinine clearance >= 30 mL/ min determined by either: a) Estimation
using the Cockcroft-Gault equation or b) Measurement by nuclear medicine
scan or 24 hour urine collection
- Total bilirubin =< 1.5 x upper limit of normal (ULN) (unless documented
Gilbert's syndrome)
- Aspartate transferase (AST) / alanine transaminase (ALT) =< 3 x ULN
- Patients should not be considered candidates for stem cell transplant or
must have declined a stem cell transplant strategy
- No clinically significant cardiovascular disease including the following
- Unstable angina within 3 months before registration
- New York Heart Association class III or IV congestive heart failure
- History of clinically significant arrhythmias (eg, sustained ventricular
tachycardia, ventricular fibrillation, torsades de pointes)
- QT correction formula (QTcF) > 480 msecs based on Fredericia's formula
- History of Mobitz II second-degree or third-degree heart block without a
permanent pacemaker in place
- Human immunodeficiency virus (HIV)-infected patients on effective
anti-retroviral therapy with undetectable viral load within 6 months are
eligible for this trial
- No active Hepatitis B or Hepatitis C infection. Patients with prior
hepatitis B virus (HBV) exposure (positive HBV core antibody and/or
surface antigen) are eligible if they have no detectable viral load, and
are taking appropriate prophylactic antiviral therapy to prevent
reactivation. Patients with history of hepatitis C virus (HCV) are
eligible if they have an undetectable HCV viral load
- Patients with a prior or concurrent malignancy whose natural history or
treatment does not have the potential to interfere with the safety or
efficacy assessment of the investigational regimen are eligible for this
trial
- No history of severe bleeding disorder such as hemophilia A, hemophilia B,
von Willebrand disease, or history of spontaneous bleeding requiring blood
transfusion or other medical intervention
- No history of stroke or intracranial hemorrhage within 6 months prior to
registration
- No disease significantly affecting gastrointestinal function such as
malabsorption syndrome, resection of the stomach or small bowel, bariatric
surgery procedures, symptomatic inflammatory bowel disease, or partial or
complete bowel obstruction. Patient must be able to swallow pills
- Potential trial participants should have recovered from major surgery
- No vaccination with a live vaccine within 35 days prior to registration
- No hypersensitivity to zanubrutinib or rituximab or any of the other
ingredients of the study drugs
- Chronic concomitant treatment with strong inhibitors of CYP3A4 is not
allowed on this study. Patients on strong CYP3A4 inhibitors must
discontinue the drug for 14 days prior to registration on the study.
- Chronic concomitant treatment with strong CYP3A4 inducers is not allowed.
Patients must discontinue the drug 14 days prior to the start of study
treatment
- Avoid use of moderate CYP3A4 inhibitors, PGP inhibitors, and moderate
CYP3A4 inducers
- Archival tissue must be available for submission in all patients for
histopathology review, though participation in correlative substudies is
optional
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Induction therapy (Zanubrutinib, rituximab) |
Patients receive zanubrutinib PO and rituximab IV on study. Patients undergo bone marrow biopsy and FDG PET/CT or CT throughout the trial. Patients may also undergo EDG and/or colonoscopy on study as clinically indicated. Patients may optionally undergo blood sample collection throughout the trial. |
|
|
Experimental Arm A (Zanubrutinib) |
Patients receive zanubrutinib PO until first disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial. |
|
|
Active Comparator ARM B (Observation) |
Patients undergo observation until first disease progression and then receive zanubrutinib PO until second disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial. |
|
Recruiting Locations
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Beverly Hills, California 90211
Los Angeles, California 90048
Site Public Contact
310-423-8965
Derby, Connecticut 06418
Fairfield, Connecticut 06824
Glastonbury, Connecticut 06033
Greenwich, Connecticut 06830
Guilford, Connecticut 06437
Hartford, Connecticut 06105
New Haven, Connecticut 06520
North Haven, Connecticut 06473
Stamford, Connecticut 06902
Torrington, Connecticut 06790
Trumbull, Connecticut 06611
Waterbury, Connecticut 06708
Waterford, Connecticut 06385
Newark, Delaware 19713
Newark, Delaware 19713
Atlanta, Georgia 30303
Site Public Contact
404-778-1868
Atlanta, Georgia 30308
Site Public Contact
888-946-7447
Atlanta, Georgia 30322
Site Public Contact
404-778-1868
Atlanta, Georgia 30342
Site Public Contact
404-851-7115
Augusta, Georgia 30912
Johns Creek, Georgia 30097
Boise, Idaho 83706
Boise, Idaho 83712
Caldwell, Idaho 83605
Coeur d'Alene, Idaho 83814
Fruitland, Idaho 83619
Meridian, Idaho 83642
Nampa, Idaho 83687
Nampa, Idaho 83687
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Bloomington, Illinois 61704
Canton, Illinois 61520
Carthage, Illinois 62321
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Danville, Illinois 61832
Decatur, Illinois 62526
Decatur, Illinois 62526
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Effingham, Illinois 62401
Effingham, Illinois 62401
Eureka, Illinois 61530
Galesburg, Illinois 61401
Kewanee, Illinois 61443
Macomb, Illinois 61455
Mattoon, Illinois 61938
O'Fallon, Illinois 62269
Ottawa, Illinois 61350
Pekin, Illinois 61554
Peoria, Illinois 61615
Peru, Illinois 61354
Princeton, Illinois 61356
Shiloh, Illinois 62269
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Urbana, Illinois 61801
Washington, Illinois 61571
Crown Point, Indiana 46307
Site Public Contact
219-310-2550
Dyer, Indiana 46311
Site Public Contact
219-924-8178
Hobart, Indiana 46342
Site Public Contact
219-947-1795
Hobart, Indiana 46342
Indianapolis, Indiana 46312
Munster, Indiana 46321
Site Public Contact
219-836-3349
Munster, Indiana 46321
Valparaiso, Indiana 46383
Ames, Iowa 50010
Site Public Contact
515-956-4132
Ames, Iowa 50010
Ankeny, Iowa 50023
Site Public Contact
515-241-3305
Boone, Iowa 50036
Site Public Contact
515-956-4132
Carroll, Iowa 51401
Clive, Iowa 50325
Site Public Contact
515-241-3305
Des Moines, Iowa 50309
Site Public Contact
515-241-6727
Des Moines, Iowa 50309
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-282-2200
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Fort Dodge, Iowa 50501
Site Public Contact
515-956-4132
Fort Dodge, Iowa 50501
Iowa City, Iowa 52242
Site Public Contact
800-237-1225
Jefferson, Iowa 50129
Site Public Contact
515-956-4132
Marshalltown, Iowa 50158
Site Public Contact
515-956-4132
Waukee, Iowa 50263
Site Public Contact
515-241-3305
Hays, Kansas 67601
Site Public Contact
785-623-5774
Kansas City, Kansas 66160
Lawrence, Kansas 66044
Olathe, Kansas 66061
Overland Park, Kansas 66210
Pittsburg, Kansas 66762
Salina, Kansas 67401
Topeka, Kansas 66606
Site Public Contact
785-295-8000
Westwood, Kansas 66205
Boston, Massachusetts 02115
Ann Arbor, Michigan 48106
Bay City, Michigan 48706
Brighton, Michigan 48114
Brighton, Michigan 48114
Canton, Michigan 48188
Canton, Michigan 48188
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Clarkston, Michigan 48346
Detroit, Michigan 48201
Farmington Hills, Michigan 48334
Farmington Hills, Michigan 48336
Site Public Contact
248-551-7695
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48532
Lapeer, Michigan 48446
Livonia, Michigan 48154
Macomb, Michigan 48044
Mount Pleasant, Michigan 48858
Petoskey, Michigan 49770
Pontiac, Michigan 48341
Royal Oak, Michigan 48073
Site Public Contact
248-551-7695
Saginaw, Michigan 48601
Tawas City, Michigan 48764
Troy, Michigan 48085
Site Public Contact
248-551-7695
Ypsilanti, Michigan 48106
Ypsilanti, Michigan 48197
Bemidji, Minnesota 56601
Brainerd, Minnesota 56401
Coon Rapids, Minnesota 55433
Deer River, Minnesota 56636
Duluth, Minnesota 55805
Hibbing, Minnesota 55746
Site Public Contact
218-786-3308
Maplewood, Minnesota 55109
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55415
Saint Cloud, Minnesota 56303
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55102
Sandstone, Minnesota 55072
Virginia, Minnesota 55792
Woodbury, Minnesota 55125
Cape Girardeau, Missouri 63703
Chesterfield, Missouri 63017
Site Public Contact
314-205-6936
City of Saint Peters, Missouri 63376
Creve Coeur, Missouri 63141
Kansas City, Missouri 64108
Site Public Contact
816-404-4375
Kansas City, Missouri 64116
Site Public Contact
913-588-3671
Kansas City, Missouri 64128
Site Public Contact
800-525-1483
Kansas City, Missouri 64154
Lee's Summit, Missouri 64064
Springfield, Missouri 65804
Site Public Contact
417-269-4520
Springfield, Missouri 65807
Site Public Contact
417-269-4520
St Louis, Missouri 63110
St Louis, Missouri 63128
St Louis, Missouri 63129
St Louis, Missouri 63136
Anaconda, Montana 59711
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Kalispell, Montana 59901
Missoula, Montana 59804
Bellevue, Nebraska 68123
Omaha, Nebraska 68118
Site Public Contact
402-559-5600
Omaha, Nebraska 68198
Lebanon, New Hampshire 03756
Camillus, New York 13031
Site Public Contact
315-472-7504
East Syracuse, New York 13057
Site Public Contact
315-472-7504
Mineola, New York 11501
New York, New York 10016
New York, New York 10065
Site Public Contact
212-746-1848
Rochester, New York 14642
Site Public Contact
585-275-5830
Webster, New York 14580
Chapel Hill, North Carolina 27599
Durham, North Carolina 27710
Site Public Contact
888-275-3853
Bismarck, North Dakota 58501
Fargo, North Dakota 58103
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Lawton, Oklahoma 73505
Site Public Contact
877-231-4440
Oklahoma City, Oklahoma 73104
Tulsa, Oklahoma 74146
Site Public Contact
918-505-3200
Newberg, Oregon 97132
Ontario, Oregon 97914
Oregon City, Oregon 97045
Portland, Oregon 97213
Portland, Oregon 97225
Providence, Rhode Island 02903
Site Public Contact
401-444-1488
Westerly, Rhode Island 02891
Boiling Springs, South Carolina 29316
Charleston, South Carolina 29425
Easley, South Carolina 29640
Greenville, South Carolina 29605
Greenville, South Carolina 29605
Greenville, South Carolina 29615
Greer, South Carolina 29650
Seneca, South Carolina 29672
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57117-5134
Salt Lake City, Utah 84112
Saint Johnsbury, Vermont 05819
Richmond, Virginia 23235
Richmond, Virginia 23298
Edmonds, Washington 98026
Issaquah, Washington 98029
Seattle, Washington 98122
Appleton, Wisconsin 54911
Appleton, Wisconsin 54911
Ashland, Wisconsin 54806
Eau Claire, Wisconsin 54701
Johnson Creek, Wisconsin 53038
La Crosse, Wisconsin 54601
Madison, Wisconsin 53718
Madison, Wisconsin 53792
Marshfield, Wisconsin 54449
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
Minocqua, Wisconsin 54548
Mukwonago, Wisconsin 53149
New Berlin, Wisconsin 53151
Site Public Contact
414-805-0505
Oconomowoc, Wisconsin 53066
Site Public Contact
262-928-7878
Rice Lake, Wisconsin 54868
Stevens Point, Wisconsin 54482
Waukesha, Wisconsin 53188
Weston, Wisconsin 54476
More Details
- NCT ID
- NCT05976763
- Status
- Recruiting
- Sponsor
- Alliance for Clinical Trials in Oncology
Detailed Description
PRIMARY OBJECTIVE: I. To compare time to first progression or death (progression free survival [PFS]1) with continuous treatment (Arm A) and time to second progression or death (PFS2) with intermittent treatment that is restarted at first progression (Arm B). KEY SECONDARY OBJECTIVE: I. To compare overall survival between patients who achieve a complete remission (CR) with induction therapy subsequently treated with continuous treatment versus (vs.) intermittent treatment as part of maintenance therapy. SECONDARY OBJECTIVES: I. To determine overall response rate (ORR) and CR rate to induction therapy with zanubrutinib and rituximab in previously untreated MCL. II. To determine adverse events during induction and post-induction in each study arm (Arm A and B) by Common Terminology Criteria for Adverse Events (CTCAE) 5.0. III. To determine PFS1, event free survival (EFS) and overall survival (OS) in each study arm (A and B). IV. To determine the overall response rate (ORR) and complete response rate (CR) after restarting zanubrutinib, following the first progression, in the intermittent treatment arm (Arm B). V. To compare burden of symptomatic adverse events (AEs) as assessed by Patient-Reported Outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE) between patients randomized to Arm A versus Arm B. QUALITY OF LIFE PRIMARY OBJECTIVE: I. To compare health-related quality of life (QOL) at 12 cycles post-randomization as assessed by the Functional Assessment of Cancer Therapy (FACT) Lymphoma Symptom Index-18 (FLYMSI-18) total score between patients randomized to Arm A versus Arm B. QUALITY OF LIFE SECONDARY OBJECTIVES: I. To compare health-related QOL at other time points as assessed by the FLYMSI-18 total score between patients randomized to Arm A versus Arm B. II. To compare burden of symptomatic AEs as assessed by PRO-CTCAE between patients randomized to continuous (Arm A) versus intermittent (Arm B) zanubrutinib treatment. QUALITY OF LIFE EXPLORATORY OBJECTIVES: I. To compare the geriatric functional and cognitive PRO as assessed by Elderly Functional Index (EFLI) and Neurology (Neuro) QOL in Arm A versus Arm B. II. To compare cognitive function at various time points as assessed by the Neuro-QOL between patients randomized to continuous (Arm A) versus intermittent (Arm B) zanubrutinib treatment. EXPLORATORY OBJECTIVES: I. To evaluate the completion rate of a lymphoma-specific patient assessment of life survey (PALS) with patient directed questions on life, health, and social determinants of health (SDH) and assess the impact of the survey collected data on outcomes for all enrolled patients (study arms A and B). II. To evaluate minimal residual disease (MRD) in those patients who achieve a CR after induction therapy (arms A and B) and how detectable MRD status changes after continued therapy vs. discontinuation of therapy (i.e. arms A vs. B). OUTLINE: INDUCTION THERAPY: Patients receive zanubrutinib orally (PO) and rituximab intravenously (IV) on study. Patients undergo bone marrow biopsy and fluciclovine F18 (FDG) positron emission tomography (PET)/ computed tomography (CT) or CT throughout the trial. Patients may also undergo esophagogastroduodenoscopy (EGD) and/or colonoscopy on study as clinically indicated. Patients may optionally undergo blood sample collection throughout the trial. MAINTENANCE THERAPY: Patients achieving a CR after induction therapy are randomized to 1 of 2 arms. ARM A: Patients receive zanubrutinib PO until first disease progression on study. Patients undergo CT or magnetic resonance imaging (MRI) or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial. ARM B: Patients undergo observation until first disease progression and then receive zanubrutinib PO until second disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial. After completion of study treatment, patients are followed within 30 days and every 6 months for 10 years.